Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
−75JPY
−589.21 MJPY
61.11 MJPY
4.15 M
About CYFUSE BIOMEDICAL K K
Sector
Industry
CEO
Shizuka Akieda
Website
Headquarters
Minato-ku
Employees (FY)
21
Founded
2010
ISIN
JP3311800001
FIGI
BBG01B7D9B40
Cyfuse Biomedical KK develops and manufactures cell regenerative systems. It focuses on developing arteries using patient's skin cells and three-dimensional (3D) printing. The firm's business activities encompass development, manufacturing, and sales of 3D tissue products. It also offers Regenova, a robotic system that facilitates the fabrication of 3D cellular structures by placing cellular spheroids in fine needle arrays according to pre-designed 3D data. The company was founded by Koji Kuchiishi and Koichi Nakayama on August 11, 2010 and is headquartered in Minato-ku, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4892 is 697 JPY — it has decreased by 0.57% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange CYFUSE BIOMEDICAL K K stocks are traded under the ticker 4892.
CYFUSE BIOMEDICAL K K is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
4892 stock is 1.43% volatile and has beta coefficient of 0.51. Check out the list of the most volatile stocks — is CYFUSE BIOMEDICAL K K there?
Yes, you can track CYFUSE BIOMEDICAL K K financials in yearly and quarterly reports right on TradingView.
4892 stock has risen by 0.87% compared to the previous week, the month change is a 5.68% fall, over the last year CYFUSE BIOMEDICAL K K has showed a 49.78% decrease.
4892 net income for the last quarter is −54.63 M JPY, while the quarter before that showed −169.98 M JPY of net income which accounts for 67.86% change. Track more CYFUSE BIOMEDICAL K K financial stats to get the full picture.
Today CYFUSE BIOMEDICAL K K has the market capitalization of 5.54 B, it has increased by 1.01% over the last week.
No, 4892 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 4892 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYFUSE BIOMEDICAL K K stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 21.00 employees. See our rating of the largest employees — is CYFUSE BIOMEDICAL K K on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CYFUSE BIOMEDICAL K K technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CYFUSE BIOMEDICAL K K stock shows the sell signal. See more of CYFUSE BIOMEDICAL K K technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CYFUSE BIOMEDICAL K K EBITDA is −659.31 M JPY, and current EBITDA margin is −1.08 K%. See more stats in CYFUSE BIOMEDICAL K K financial statements.